Chronic Bacterial Infection Prevalence, Risk Factors, and Characteristics: A Bronchiectasis Population-Based Prospective Study.
Pseudomonas aeruginosa
bronchiectasis
chronic bacterial infection
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
06 Mar 2019
06 Mar 2019
Historique:
received:
15
02
2019
revised:
27
02
2019
accepted:
01
03
2019
entrez:
9
3
2019
pubmed:
9
3
2019
medline:
9
3
2019
Statut:
epublish
Résumé
Few data are available on chronic bacterial infections (CBI) in bronchiectasis patients. Given that CBI seems to trigger longer hospital stays, worse outcomes, and morbimortality, this study was undertaken to assess CBI prevalence, characteristics, and risk factors in outpatients with bronchiectasis. A total of 186 patients followed in a bronchiectasis tertiary referral centre in Portugal were included. Demographic data and information on aetiology, smoking history, mMRC score, Bronchiectasis Severity Index (BSI) score, sputum characteristics, lung function, exacerbations, and radiological involvement degree were collected. Patients included (mean age 54.7 ± 16.2 years; 60.8% females) were followed up for a period of 3.8 ± 1.7 years. The most common cause of bronchiectasis was infection (31.7%) followed by immune deficiencies (11.8%), whereas in 29% of cases, no cause was identified. According to the CBI status, two different sub-groups of patients were found on the basis of several clinical outcomes, emphasizing the importance of routine sputum microbiological monitoring. Further studies are needed to better characterize CBI profiles and to define the individual clinical impact of the most prevalent pathogenic microorganisms.
Sections du résumé
BACKGROUND
BACKGROUND
Few data are available on chronic bacterial infections (CBI) in bronchiectasis patients. Given that CBI seems to trigger longer hospital stays, worse outcomes, and morbimortality, this study was undertaken to assess CBI prevalence, characteristics, and risk factors in outpatients with bronchiectasis.
METHODS
METHODS
A total of 186 patients followed in a bronchiectasis tertiary referral centre in Portugal were included. Demographic data and information on aetiology, smoking history, mMRC score, Bronchiectasis Severity Index (BSI) score, sputum characteristics, lung function, exacerbations, and radiological involvement degree were collected.
RESULTS
RESULTS
Patients included (mean age 54.7 ± 16.2 years; 60.8% females) were followed up for a period of 3.8 ± 1.7 years. The most common cause of bronchiectasis was infection (31.7%) followed by immune deficiencies (11.8%), whereas in 29% of cases, no cause was identified.
CONCLUSION
CONCLUSIONS
According to the CBI status, two different sub-groups of patients were found on the basis of several clinical outcomes, emphasizing the importance of routine sputum microbiological monitoring. Further studies are needed to better characterize CBI profiles and to define the individual clinical impact of the most prevalent pathogenic microorganisms.
Identifiants
pubmed: 30845638
pii: jcm8030315
doi: 10.3390/jcm8030315
pmc: PMC6463080
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Radiology. 1991 Jun;179(3):783-8
pubmed: 2027992
Thorax. 2002 Jan;57(1):15-9
pubmed: 11809984
Rev Port Pneumol (2006). 2016 Jul-Aug;22(4):222-35
pubmed: 27134122
Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416
pubmed: 17277290
Eur Respir J. 2006 Nov;28(5):974-9
pubmed: 16899482
Chest. 1995 Oct;108(4):955-61
pubmed: 7555168
Eur Respir J. 2008 Feb;31(2):396-406
pubmed: 18238949
Am J Respir Crit Care Med. 2006 Feb 1;173(3):327-33
pubmed: 16254274
Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1277-84
pubmed: 11029331
Am J Respir Crit Care Med. 2014 Mar 1;189(5):576-85
pubmed: 24328736
Respir Med. 2015 Jun;109(6):716-26
pubmed: 25200914
Eur Respir J. 2018 Jan 31;51(2):
pubmed: 29386336
Arch Bronconeumol. 2009 Dec;45(12):597-602
pubmed: 19875219
Eur Respir J. 2016 Apr;47(4):1113-22
pubmed: 26846833
Tuberk Toraks. 2011;59(4):340-7
pubmed: 22233303
Eur Respir J. 2005 Nov;26(5):948-68
pubmed: 16264058
Chest. 2006 Nov;130(5):1424-32
pubmed: 17099020
Breathe (Sheff). 2016 Sep;12(3):222-235
pubmed: 28210295
Thorax. 2013 Aug;68(8):731-7
pubmed: 23564400
Respir Med. 2007 Aug;101(8):1633-8
pubmed: 17467966
Respir Med. 2007 Jun;101(6):1163-70
pubmed: 17223027
Chest. 2008 Oct;134(4):815-823
pubmed: 18842914
Eur Respir J. 2005 Jul;26(1):153-61
pubmed: 15994402
PLoS One. 2017 Feb 7;12(2):e0170622
pubmed: 28170403
Eur Respir J. 2017 Jun 8;49(6):
pubmed: 28596426
Respir Med. 2013 Jan;107(1):10-22
pubmed: 23218452
Ann Am Thorac Soc. 2015 Nov;12(11):1602-11
pubmed: 26356317
Respir Med. 2006 Dec;100(12):2183-9
pubmed: 16650970
Eur Respir J. 2009 Aug;34(2):361-4
pubmed: 19648517